Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AWK$142.08-0.67(-0.47%)American Water Contributes Expertise at California Water Association 2026 Summit American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., will join important conversations and contribute...[9:03:00 AM ET]TFC$48.91+0.47(+0.97%)Truist names Alex Bartlett regional president for Greater Washington and Maryland Truist Financial Corporation (NYSE: TFC) today announced Alex Bartlett has been named regional president for Greater Washington and Maryland. A...[9:03:00 AM ET]MKTW$19.58+0.75(+3.98%)MarketWise, Inc. Declares Quarterly Dividend on Class A Common Stock of $0.45 Per Share[9:00:14 AM ET]UFPI$80.93-0.30(-0.37%)UFP Packaging Expands Gulf Coast Pallet Network with Acquisition of Apache Products UFP Packaging, a division of UFP Industries (Nasdaq: UFPI), announced this week the acquisition of Apache Products, Inc., a pallet producer based in...[9:00:00 AM ET]THFF$77.70+1.24(+1.62%)First Financial Corporation Reports Third Quarter Results[9:00:00 AM ET]FTNT$181.84-1.49(-0.81%)Fortinet Expands Unified SASE to Simplify Microbranch Security[9:00:00 AM ET]VELO$6.61+0.12(+1.85%)Velo3D to Announce Third Quarter 2026 Results on November 10, 2026 Velo3D, Inc. (Nasdaq: VELO), a leading metal additive manufacturing technology company, today announced that it will release its third quarter 2026...[9:00:00 AM ET]CPB$20.53-0.10(-0.48%)Campbell's® Marks Five Years of Sides Season™ with Its Annual State of the Sides Report Campbell's officially kicked off Sides Season™ with the release of its 2026 State of the Sides Report. Now in its fifth year, the report offers a...[9:00:00 AM ET]TENB$47.55-0.66(-1.37%)Tenable Selected by Atos to Power Continuous Threat Exposure Management Program[9:00:00 AM ET]PLUR$1.23+0.11(+9.82%)Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments[9:00:00 AM ET]ATYR$0.12-0.03(-21.71%)aTyr Pharma Announces One-for-40 Reverse Stock Split[9:00:00 AM ET]KD$14.70+0.02(+0.14%)Kyndryl Opens New Cyber Defense Operations Center in Paris Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today unveiled a new Cyber Defense Operations Center in...[9:00:00 AM ET]DVN$51.27-0.37(-0.72%)NEQ Operating Strengthens Leadership Team to Support Next Phase of Growth[9:00:00 AM ET]

ARTV · NASDAQ

Artiva Biotherapeutics, Inc.

$4.15 -2.01 (-32.63%)

Company overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, including lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$203M
Employees
96
Headquarters
San Diego, CA
Website
artivabio.com
CEO
Fred Aslan
Listed
July 19, 2024
P/E
-1.17
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$666,000
Operating income
-$92.1M
EBITDA
-$89.4M
Net income
-$87.1M
EPS
-$3.55
Total assets
$106M
Total debt
$10.3M
Earnings yield
-85.75%

Price chart

5.477.439.3811.3313.29
ARTV 1D NASDAQ O6.04H6.19L5.96C6.16+0.01 (+0.16%)Vol141.66K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK® GlobeNewswire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Announces Multiple AlloNK® Data GlobeNewswire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Highlights Updated AlloNK® Data in GlobeNewswire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026) GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 GlobeNewswire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Zacks Investment Research
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA Seeking Alpha
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics Stock Slides Despite Positive Trial Data Benzinga
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights Globe News Wire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 Globe News Wire
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham Defense World
ARTVArtiva Biotherapeutics, Inc. Press release Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference GlobeNewsWire
ARTVArtiva Biotherapeutics, Inc. Stock news Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest Defense World
See more
FAQ

Questions about Artiva Biotherapeutics, Inc.

What does Artiva Biotherapeutics, Inc. do?
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, including lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
What is ARTV's market cap?
Artiva Biotherapeutics, Inc. (ARTV) is a listed stock with a live quote. The latest market cap on this page is $203M.
Where is Artiva Biotherapeutics, Inc. headquartered?
Artiva Biotherapeutics, Inc. is headquartered in San Diego, CA.
How do I get ARTV news from the API?
Call GET /v1/news?tickers=ARTV. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ARTV news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ARTV, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ARTV price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs